Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| TIEWX | 15.66 | 0.13 | +0.84% |
| Nuveen International Eq W | |||
| SSILX | 13.79 | 0.11 | +0.80% |
| State Street International Stock Sel A | |||
| IYBIX | 24.76 | 0.11 | +0.45% |
| Macquarie Balanced Fund Class I | |||
| HBFBX | 12.12 | 0.02 | +0.17% |
| Hennessy Balanced Investor | |||
| BPSCX | 24.39 | 0.04 | +0.16% |
| Boston Partners Small Cap Value II Inv | |||
A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with CORT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then CORT could also see price increases.
| Ticker / NAME | Correlation To HNSBF | 1D Price Change % | ||
|---|---|---|---|---|
| HNSBF | 100% | N/A | ||
| CORT - HNSBF | 38% Loosely correlated | -1.49% | ||
| AVXL - HNSBF | 36% Loosely correlated | -0.94% | ||
| PMVP - HNSBF | 31% Poorly correlated | -0.93% | ||
| MLLCF - HNSBF | 28% Poorly correlated | N/A | ||
| ELTX - HNSBF | 27% Poorly correlated | N/A | ||
More | ||||